Track market-moving stories before they get noisy

PHILADELPHIA, Aug. 27, 2026 /PRNewswire/ -- FMC Corporation (NYSE: FMC) today announced that Pierre Brondeau, FMC chairman, chief executive officer and president, and Andrew Sandifer, FMC executive vice president and chief financial officer, will speak at the 2026 Jefferies Global Industrials Conference on September 10, 2026 at 11:30 a.m. Eastern Time.

NEW YORK--(BUSINESS WIRE)-- #creditratingagency--KBRA assigns ratings of ‘BBB- (sf)' to the Series 2026-GT1, Class A Term Notes from FMC GMSR ISSUER TRUST, Freedom Mortgage Corporation's (FMC) master trust issuer of notes backed by a participation certificate evidencing a participation interest in mortgage servicing rights (MSR) on loans underlying Ginnie Mae guaranteed mortgage backed securities. KBRA's rating on the Series 2026-GT1 Term Notes is primarily driven by the credit rating of Freedom Mortgage Corporation.

Have you evaluated the performance of FMC's (FMC - Free Report) international operations during the quarter that concluded in June 2026? Considering the extensive worldwide presence of this chemical producer, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.

In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall financial health and growth trajectory. For investors, understanding a company's reliance on overseas markets has become increasingly crucial, as it offers insights into the company's sustainability of earnings, ability to tap into diverse economic cycles and overall growth potential.

International market involvement serves as insurance against economic downturns at home and enables engagement with economies that are growing more quickly. Still, this move toward diversification is not without its challenges, as it involves navigating through the fluctuations of currencies, geopolitical threats, and the distinctive nature of various markets.

While delving into FMC's performance for the past quarter, we observed some fascinating trends in the revenue from its foreign segments that are commonly modeled and observed by analysts on Wall Street.

The company's total revenue for the quarter stood at $841.4 million, declining 19.9% year over year. Now, let's delve into FMC's international revenue breakdown to gain insights into the significance of its operations beyond home turf.

Exploring FMC's International Revenue PatternsEurope/Middle East/Africa accounted for 25.5% of the company's total revenue during the quarter, translating to $214.1 million. Revenues from this region represented a surprise of -5.97%, with Wall Street analysts collectively expecting $227.69 million. When compared to the preceding quarter and the same quarter in the previous year, Europe/Middle East/Africa contributed $306.9 million (40.5%) and $260 million (24.8%) to the total revenue, respectively.

During the quarter, Latin America contributed $277.9 million in revenue, making up 33% of the total revenue. When compared to the consensus estimate of $286.77 million, this meant a surprise of -3.09%. Looking back, Latin America contributed $177 million, or 23.3%, in the previous quarter, and $310 million, or 29.5%, in the same quarter of the previous year.

Asia generated $126.3 million in revenues for the company in the last quarter, constituting 15% of the total. This represented a surprise of +27.87% compared to the $98.78 million projected by Wall Street analysts. Comparatively, in the previous quarter, Asia accounted for $77.1 million (10.2%), and in the year-ago quarter, it contributed $159 million (15.1%) to the total revenue.

Prospective Revenues in International MarketsWall Street analysts expect FMC to report a total revenue of $869.11 million in the current fiscal quarter, which suggests a decline of 9.6% from the prior-year quarter. Revenue shares from Europe/Middle East/Africa, Latin America and Asia are predicted to be 16.7%, 54.2%, and 10.3%, corresponding to amounts of $145.09 million, $471.13 million, and $89.8 million, respectively.

For the full year, the company is expected to generate $3.54 billion in total revenue, down 9% from the previous year. Revenues from Europe/Middle East/Africa, Latin America and Asia are expected to constitute 24.5% ($867.17 million), 37.3% ($1.32 billion) and 12.3% ($435.91 million) of the total, respectively.

Key TakeawaysRelying on global markets for revenues presents both prospects and challenges for FMC. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.

With the increasing intricacies of global interdependence and geopolitical strife, Wall Street analysts meticulously observe these patterns, especially for companies with an international footprint, to tweak their forecasts of earnings. Importantly, several additional factors, such as a company's domestic market status, also impact these earnings forecasts.

Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.

Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.

At present, FMC holds a Zacks Rank #5 (Strong Sell). This ranking implies that its near-term performance might underperform the overall market movement. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Reviewing FMC's Recent Stock Price TrendsOver the past month, the stock has seen a decline of 9% in its value, whereas the Zacks S&P 500 composite has posted an increase of 3.5%. The Zacks Consumer Staples sector, FMC's industry group, has descended 0.1% over the identical span. In the past three months, there's been a decline of 19.8% in the company's stock price, against a rise of 7.7% in the S&P 500 index. The broader sector has increased by 5.3% during this interval.

FMC (FMC - Free Report) reported $841.4 million in revenue for the quarter ended June 2026, representing a year-over-year decline of 19.9%. EPS of $0.26 for the same period compares to $0.69 a year ago.

The reported revenue represents a surprise of -7.03% over the Zacks Consensus Estimate of $905.01 million. With the consensus EPS estimate being $0.21, the EPS surprise was +23.81%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how FMC performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Geographic Revenue- North America: $248.8 million compared to the $306.74 million average estimate based on two analysts. The reported number represents a change of -22.5% year over year.Geographic Revenue- Asia: $126.3 million versus the two-analyst average estimate of $98.78 million. The reported number represents a year-over-year change of -20.6%.Geographic Revenue- Europe, Middle East and Africa (EMEA): $214.1 million compared to the $227.69 million average estimate based on two analysts. The reported number represents a change of -17.7% year over year.Geographic Revenue- Latin America: $277.9 million compared to the $286.77 million average estimate based on two analysts. The reported number represents a change of -10.4% year over year.View all Key Company Metrics for FMC here>>>

Shares of FMC have returned +4.2% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

FMC Corporation (FMC) Q2 2026 Earnings Call July 30, 2026 9:00 AM EDT

Company Participants

Curt Brooks - Director of Investor Relations
Pierre Brondeau - President, CEO & Non-Executive Chairman of the Board
Andrew Sandifer - Executive VP & CFO

Conference Call Participants

Patrick Fischer - Goldman Sachs Group, Inc., Research Division
Edlain Rodriguez - Mizuho Securities USA LLC, Research Division
Frank Mitsch - Fermium Research, LLC
Christopher Parkinson - Wolfe Research, LLC
Joel Jackson - BMO Capital Markets Equity Research
Patrick Cunningham - Citigroup Inc., Research Division
Arun Viswanathan - RBC Capital Markets, Research Division
Benjamin Theurer - Barclays Bank PLC, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for joining us, and welcome to the Second Quarter 2026 Earnings Call for FMC Corporation. This event is being recorded. [Operator Instructions] I will now hand the conference over to Mr. Curt Brooks, Director of Investor Relations for FMC Corporation. Please go ahead.

Curt Brooks
Director of Investor Relations

Good morning, and welcome to FMC Corporation's 2026 Second Quarter Earnings Call. Today's prepared remarks will be provided by Pierre Brondeau, Chairman, Chief Executive Officer and President; and Andrew Sandifer, Executive Vice President and Chief Financial Officer.

After prepared comments, we will take questions. Our earnings release and today's slide presentation are available on the FMC Investor Relations website, and the prepared remarks from today's discussion will be made available after the call.

Let me remind you that today's presentation and discussion will include forward-looking statements that are subject to various risks and uncertainties concerning specific factors, including, but not limited to, those factors identified in our earnings release and in our filings with the Securities and Exchange Commission. Information presented represents our best judgment based on today's understanding. Actual results may vary based on these risks and uncertainties.

Today's discussion and the supporting materials will include

Shares of FMC Corporation (FMC +18.18%) rallied on Thursday, up 15.8% as of 12:03 p.m. EDT.

The agricultural chemicals company reported earnings last night. While the initial market reaction was negative due to a revenue miss and guidance cut, there was apparently enough good news to trigger a relief rally in this very beaten-down stock.

Today's Change

(

18.18

%) $

1.82

Current Price

$

11.83

FMC disappoints on revenue but gets cash infusions In the second quarter, FMC's revenue declined by 17% to $867 million, missing expectations by $30 million. However, adjusted (non-GAAP) earnings per share of $0.26 beat expectations, despite falling an ignominious 62% from the prior year.

Despite the slight profit "beat," FMC also lowered its full-year guidance. Revenue is now forecast at $3.5 billion to $3.7 billion, down from a prior range of $3.6 billion to $3.8 billion. Adjusted EPS is forecast to be $1.34 at the midpoint, down from prior guidance of $1.76.

FMC has been in a severe downturn for the past couple of years, as many of the company's products have come off-patent, while farming margins have gone lower, pressuring both pricing and volume. FMC's debt is also over $4.5 billion as of June 30, making the situation even more dire.

FMC has been making moves to pay down debt, though. Notably, on July 1, European agricultural company Tessenderlo Group agreed to buy a 20% stake in FMC for $400 million. That's notable, as even after today's rise, FMC stock has only a $1.44 billion market capitalization. Additionally, FMC licensed its rimisoxafen technology to Corteva (CTVA -1.29%) in June for a $200 million upfront payment. In May, the company announced the sale of its loss-making India business to Crystal Crop Protection Limited for $252 million.

Those three items should help FMC pay down debt in the near term and contribute to management's goal of paying down $1 billion in debt this year.

Image source: Getty Images.

Not a great quarter, but mere survival is a positive Perhaps the reiteration of the 2026 debt paydown target on the earnings call was enough to cause a relief rally in FMC stock. Shares are, after all, down over 90% just since early 2023.

In any case, FMC remains an intriguing turnaround story; however, even after this year's debt paydown, its business remains questionable, and the company has fewer assets as a result of recent sales. Therefore, a bet on FMC remains highly risky and speculative.

Updates full-year outlook to reflect more challenging macro environment; Company continues to focus on execution of operational priorities

Second Quarter 2026 Highlights

Revenue of $867 million, down 17 percent versus Q2 2025 Revenue excluding India1 of $841 million, down 20 percent versus Q2 2025 (which included India) Organic revenue2 for the period declined 22 percent Consolidated GAAP net loss of $187 million, a decline of $253 million versus Q2 2025 Adjusted EBITDA of $153 million, down 26 percent versus Q2 2025 Consolidated GAAP net loss of $1.49 per diluted share, down $2.02 versus Q2 2025 Adjusted earnings per diluted share of $0.26, down 62% versus Q2 2025 GAAP cash from operations of $363 million, an increase of $297 million versus Q2 2025 Full-Year Outlook1

Revenue excluding India lowered to a range of $3.50 billion to $3.70 billion, a decline of 7 percent at the midpoint versus 2025 Excluding 2025 India contributions, the 2026 outlook represents a decline at the midpoint of 5 percent Adjusted EBITDA lowered to a range of $620 million to $680 million, a decline of 23 percent at the midpoint Adjusted earnings per diluted share lowered to a range of $1.19 to $1.49, a decline of 55 percent at the midpoint Free cash flow, which now includes the upfront licensing payment for rimisoxafen of $200 million, increased to a range of $75 million to $225 million , /PRNewswire/ -- FMC Corporation (NYSE: FMC) today reported second quarter 2026 revenue of $867 million, down 17 percent versus second quarter 2025.  Second quarter 2026 revenue, excluding India, was $841 million, down 20 percent versus second quarter 2025, which included India.  On a GAAP basis, the company reported a loss of $1.49 per diluted share in the second quarter, a decrease of $2.02 versus second quarter 2025.  Second quarter adjusted earnings per diluted share of $0.26 was down 62 percent versus second quarter 2025.

"During the quarter, we completed several important actions that strengthened FMC's financial foundation and provide greater flexibility to execute our strategy," said Pierre Brondeau, chairman, chief executive officer and president. "With the strategic review now concluded, we have clarity on the path forward and remain focused on improving competitiveness, advancing our technology portfolio and positioning the company for long-term growth."

FMC Revenue

Q2 2026

Total Revenue Change (GAAP)

(17) %

Total Revenue Change (ex-India) (Non-GAAP)

(20) %

Less: 2025 revenue for India held for sale business

(5) %

Like-for-Like Revenue Change (Non-GAAP)

(15) %

Second quarter sales of $841 million, excluding India, were 20 percent lower than prior year.  The removal of India represented a 5 percent sales headwind.  Volumes declined 10 percent due to lower diamide partner orders and reduced demand for core legacy products, particularly in North America, as growers contend with strained margins. Price declined 7 percent, driven by pressure on the company's core legacy products and planned Rynaxypyr® active pricing actions.  Foreign currency was a 2 percent tailwind.  The growth portfolio grew mid-single digits as lower Plant Health sales were more than offset by strong performances from new active ingredients and Cyazypyr® active, reflecting continued demand for innovative solutions. Branded sales of Rynaxypyr® were essentially flat versus prior year, excluding India, with strong demand for new formulations.

FMC Regional Revenue ($M)

Q2 2026

Q2 2025

North America

$249

$321

Latin America

$278

$310

EMEA

$214

$260

Asia (excluding 2026 India)1

$101

$159

2026 India1

$26

—

Total Revenue (GAAP)

$867

$1,051

Totals may not sum due to rounding

GAAP net loss in the second quarter declined $253 million primarily due to lower sales, higher restructuring costs and higher interest expense. FMC second quarter Adjusted EBITDA was $153 million, a decrease of 26 percent from the prior-year period.  Lower price and volume were partially offset by favorable costs and a moderate FX tailwind.

On a GAAP basis, cash from operations for the second quarter was $363 million, an increase of $297 million versus 2025, including a $200 million upfront payment related to the rimisoxafen active ingredient licensing agreement.  Free cash flow was $357 million, an improvement of $318 million versus Q2 2025 primarily due to higher cash from operations.

Strategy Update

FMC continued to make progress on its four operational pillars during the second quarter: reducing debt, improving the competitiveness of its core portfolio, managing the post-patent transition for Rynaxypyr® and accelerating growth of new active ingredients. These pillars remain the foundation of the company's plan to improve earnings and cash generation, positioning FMC to take full advantage of its technology-driven growth potential.

During the quarter, FMC announced the key components of its targeted approximately $1 billion of proceeds to be used for debt reduction. These actions included signing a definitive agreement for the sale of its India commercial business for $252 million, closing on a licensing agreement for rimisoxafen with Corteva for an upfront payment of $200 million, signing a sale-leaseback agreement for its Newark, Delaware property for $114 million and reaching an agreement for a $400 million equity investment from Tessenderlo Group. With these actions and other minor asset sales to be completed this year, FMC expects to generate approximately $1 billion of proceeds to be used for debt paydown.  The India commercial business sale, the Newark, Delaware property sale and the Tessenderlo Group investment are subject to various closing conditions, including regulatory approvals.

With these actions in place, the FMC Board of Directors has concluded the exploration of strategic options announced in February 2026. The company remains focused on executing its operational priorities and strengthening the foundation for future growth through its differentiated technology portfolio.

Full Year Outlook1

The company has updated its full-year 2026 revenue, Adjusted EBITDA, Adjusted EPS and free cash flow guidance ranges.  Full year 2026 revenue guidance1 is now $3.50 billion to $3.70 billion, a decline of 7 percent at the midpoint versus prior year1. The updated guidance reflects a more challenging operating environment and incorporates the company's current view of customer purchasing patterns and market conditions.  Price is expected to be lower by mid-to-high single digits mainly due to a challenging macro environment as well as planned pricing actions for Rynaxypyr®. Excluding India, volume is expected to be in line with prior year as reduced diamide partner orders are offset by growth in nearly all other parts of the portfolio. India represents a 2 percent headwind1. FX is expected to be a low-single digit tailwind.

Adjusted EBITDA is expected to be $620 million to $680 million, a decline of 23 percent versus prior year, as lower price and an FX headwind are partially offset by favorable costs. Adjusted EPS is expected to be $1.19 to $1.49, a decrease of 55 percent versus prior year, primarily due to lower Adjusted EBITDA and increased interest expense. Free cash flow is expected to be $75 million to $225 million.  Free cash flow guidance now includes the $200 million upfront payment received for rimisoxafen licensing.

Third Quarter and Fourth Quarter Outlooks1

Third quarter revenue excluding India is expected to be in the range of $840 million to $900 million, down 9 percent at the midpoint versus third quarter 2025. Price is expected to be lower by mid-to-high single digits. FX is expected to be neutral. Volume is expected to be lower as distributors in North America shift orders from Q3 to Q4 to align purchases more closely with application timing and manage inventory levels. Adjusted EBITDA is forecasted to be in the range of $120 million to $140 million, a decrease of 45 percent at the midpoint versus the prior year as lower sales and an FX headwind are partially offset by favorable costs. FMC expects adjusted earnings per diluted share to be in the range of $0.05 to $0.13 in the third quarter, which represents a 90 percent decline at the midpoint versus third quarter 2025 driven mainly by lower adjusted EBITDA and higher interest expense.

The company expects a return to year-over-year growth in the fourth quarter. Fourth quarter revenue excluding India is expected to be in the range of $1.06 billion to $1.20 billion, an increase of 4 percent at the midpoint versus fourth quarter 2025. Volume is expected to show healthy growth driven by increased direct sales to growers in Brazil, new active ingredients and North America distributor orders that shifted from Q3 to Q4. Price is expected to decline by mid-to-high single digits.  Adjusted EBITDA is forecasted to be in the range of $275 million to $315 million, an increase of 5 percent at the midpoint versus the prior year as lower price and an FX headwind are more than offset by higher volume and favorable costs.  FMC expects adjusted earnings per diluted share to be in the range of $1.09 to $1.33 in the fourth quarter, which represents a 1 percent increase at the midpoint versus fourth quarter 2025.

Full-Year 2026 Outlook1

 H2 2026    Outlook1

Third Quarter Outlook1

Fourth Quarter Outlook1

Revenue Excl. India

$3.50 billion to

$3.70 billion

$1.90 billion to

$2.10 billion

$840 million to

$900 million

$1.06 billion to

$1.20 billion

Growth at midpoint vs. 2025*

(7) %

(2) %

(9) %

4 %

Adjusted EBITDA

$620 million to

$680 million

$395 million to

$455 million

$120 million to

$140 million

$275 million to

$315 million

Growth at midpoint vs. 2025*

(23) %

(18) %

(45) %

5 %

Adjusted EPS^

$1.19 to $1.49

$1.16 to $1.46

$0.05 to $0.13

$1.09 to $1.33

Growth at midpoint vs. 2025*

(55) %

(37) %

(90) %

1 %

^ EPS estimates assume 125.9 million diluted shares for full year, H2, Q3 and Q4

*Percentages are calculated using whole numbers.  Minor differences may exist due to rounding.  India excluded from 2026 guidance and H2 2025

Supplemental Information

The company will post supplemental information on the web at https://investors.fmc.com, including its webcast slides for tomorrow's earnings call, definitions of non-GAAP terms and reconciliations of non-GAAP figures to the nearest available GAAP term.

Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions. FMC, the FMC logo, Cyazypyr and Rynaxypyr are trademarks of FMC Corporation or an affiliate.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995:  FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaim any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

This press release contains certain "non-GAAP financial terms" which are defined on our website www.fmc.com/investors. Such terms include Adjusted EBITDA, Adjusted earnings, free cash flow and organic revenue growth. In addition, we have also provided on our website reconciliations of non-GAAP terms to the most directly comparable GAAP terms.

Although we provide forecasts for adjusted earnings per share, Adjusted EBITDA, and free cash flow (non-GAAP financial measures), we are not able to forecast the most directly comparable measures calculated and presented in accordance with GAAP. Certain elements of the composition of the GAAP amounts are not predictable, making it impractical for us to forecast. Such elements include, but are not limited to, restructuring, acquisition charges, our India held for sale business, and discontinued operations. As a result, no GAAP outlook is provided. Starting with the third quarter 2025 guidance, we provide forecasts for revenue excluding India (non-GAAP financial measure). We are not able to forecast the GAAP revenue due to potential actions we may take during the held for sale period to prepare the business for a potential buyer and other uncertainties, including customer reaction to the announcement of our intention to sell our India commercial business. In 2026, revenue, Adjusted EBITDA and Adjusted EPS outlooks provided exclude India results and variances are calculated versus 2025 results, which include India results in the first half of the year.  Organic revenue growth (non-GAAP) excludes the impact of foreign currency changes and the removal of India. FMC CORPORATION

CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

(In millions, except per share amounts)

2026

2025

2026

2025

Revenue

$         867.1

$      1,050.5

$      1,625.7

$      1,841.9

Costs of sales and services

525.0

644.2

1,037.0

1,118.9

Gross margin

$         342.1

$         406.3

$         588.7

$         723.0

Selling, general and administrative expenses

179.1

176.8

364.2

348.8

Research and development expenses

60.4

66.4

125.9

135.1

Restructuring and other charges (income)

222.3

36.7

299.3

54.5

Total costs and expenses

$         986.8

$         924.1

$      1,826.4

$      1,657.3

Income from continuing operations before non-operating
pension, postretirement, and other charges (income), interest
expense, net and income taxes

$       (119.7)

$         126.4

$       (200.7)

$         184.6

Non-operating pension, postretirement, and other charges (income)

3.3

6.6

6.7

9.8

Interest expense, net

71.3

61.0

136.1

111.1

Income (loss) from continuing operations before income taxes

$       (194.3)

$           58.8

$       (343.5)

$           63.7

Provision (benefit) for income taxes

(1.5)

14.4

110.6

27.9

Income (loss) from continuing operations

$       (192.8)

$           44.4

$       (454.1)

$           35.8

Discontinued operations, net of income taxes

6.5

23.4

(13.4)

16.4

Net income (loss)

$       (186.3)

$           67.8

$       (467.5)

$           52.2

Less: Net income (loss) attributable to noncontrolling interests

0.3

1.1

0.4

1.0

Net income (loss) attributable to FMC stockholders

$       (186.6)

$           66.7

$       (467.9)

$           51.2

Amounts attributable to FMC stockholders:

  Income (loss) from continuing operations, net of tax

$       (193.1)

$           43.3

$       (454.5)

$           34.8

  Discontinued operations, net of tax

6.5

23.4

(13.4)

16.4

  Net income (loss)

$       (186.6)

$           66.7

$       (467.9)

$           51.2

Basic earnings (loss) per common share attributable to FMC
stockholders:

  Continuing operations

$         (1.54)

$           0.34

$         (3.62)

$           0.28

  Discontinued operations

0.05

0.19

(0.11)

0.13

  Basic earnings per common share

$         (1.49)

$           0.53

$         (3.73)

$           0.41

Average number of shares outstanding used in basic earnings per
share computations

125.4

125.2

125.3

125.1

Diluted earnings (loss) per common share attributable to FMC
stockholders:

  Continuing operations

$         (1.54)

$           0.34

$         (3.62)

$           0.28

  Discontinued operations

0.05

0.19

(0.11)

0.13

  Diluted earnings per common share

$         (1.49)

$           0.53

$         (3.73)

$           0.41

Average number of shares outstanding used in diluted earnings per
share computations

125.4

125.6

125.3

125.5

Other Data:

Capital additions and other investing activities

$           (6.5)

$             9.8

$             9.3

$           47.2

Depreciation and amortization expense

$          41.1

$           43.4

$           83.1

$           87.1

FMC CORPORATION

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

RECONCILIATION OF NET INCOME (LOSS) ATTRIBUTABLE TO FMC STOCKHOLDERS (GAAP) TO
ADJUSTED AFTER-TAX EARNINGS FROM CONTINUING OPERATIONS, ATTRIBUTABLE TO FMC
STOCKHOLDERS (NON-GAAP) (1)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

(In millions, except per share amounts)

2026

2025

2026

2025

Net income (loss) attributable to FMC stockholders (GAAP)

$         (186.6)

$             66.7

$      (467.9)

$          51.2

Corporate special charges (income):

Restructuring and other charges (income) (a)

148.0

36.7

242.7

54.5

Non-operating pension, postretirement, and other charges
(income) (b)

3.3

6.6

6.7

9.8

India held for sale business (c)

83.2

—

99.6

—

Income tax expense (benefit) on Corporate special charges
(income) (d)

(30.4)

(6.8)

(48.7)

(11.2)

Discontinued operations attributable to FMC stockholders, net of
income taxes (e)

(6.5)

(23.4)

13.4

(16.4)

Tax adjustment (f)

22.1

6.9

158.4

21.2

Adjusted after-tax earnings (loss) from continuing operations 
attributable to FMC stockholders (non-GAAP) (1)

$             33.1

$             86.7

$            4.2

$        109.1

Diluted earnings (loss) per common share (GAAP)

$           (1.49)

$             0.53

$        (3.73)

$          0.41

Corporate special charges (income) per diluted share, before tax:

Restructuring and other charges (income)

1.17

0.29

1.94

0.43

Non-operating pension, postretirement, and other charges
(income)

0.03

0.05

0.05

0.08

India held for sale business

0.66

—

0.79

—

Income tax expense (benefit) on Corporate special charges
(income), per diluted share

(0.24)

(0.04)

(0.39)

(0.09)

Discontinued operations attributable to FMC stockholders, net of
income taxes per diluted share 

(0.05)

(0.19)

0.11

(0.13)

Tax adjustments per diluted share

0.18

0.05

1.26

0.17

Diluted adjusted after-tax earnings (loss) from continuing
operations per share, attributable to FMC stockholders (non-
GAAP)

$             0.26

$             0.69

$          0.03

$          0.87

Average number of shares outstanding used in diluted adjusted
after-tax earnings (loss) from continuing operations per share
computations(2)

126.0

125.6

125.8

125.5

____________________

(1)

Referred to as Adjusted earnings. The Company believes that Adjusted earnings, a non-GAAP financial measure, and its presentation on a per share basis provides useful information about the Company's operating results to management, investors, and securities analysts. Adjusted earnings excludes the effects of corporate special charges, the India held for sale business, tax-related adjustments and the results of our discontinued operations. The Company also believes that excluding the effects of these items from operating results allows management and investors to compare more easily the financial performance of its underlying business from period to period.

(2)

The average number of shares outstanding used in the three and six months ended June 30, 2026 diluted adjusted after-tax earnings from continuing operations per share computation (Non-GAAP) includes 0.6 million and 0.4 million diluted shares, respectively. This number of shares differs from the average number of shares outstanding used in diluted earnings per share computations (GAAP) as we had a net loss from continuing operations attributable to FMC stockholders.

(a)

Three Months Ended June 30, 2026:

Restructuring and other charges (income) includes restructuring charges of $139.5 million primarily comprised of $136.5 million in charges related to Project Foundation, which is management's comprehensive plan to further optimize FMC's cost structure and organizational operations. The charges for Project Foundation include non-cash asset write-off and accelerated depreciation costs of $134.2 million primarily associated with the planned exit of certain production activities, which includes a write-off of $70.6 million for certain receivables due to a change in our commercial strategy in Latin America; severance and employee separation costs of $5.3 million; and, other miscellaneous income of $3.0 million, which includes cash proceeds from the sale of a legacy product line partially offset by professional service provider costs. During the three months ended June 30, 2026, we also recorded Project Focus-related costs of $2.9 million, primarily related to miscellaneous charges associated with previously implemented activities. Other charges (income) included $5.4 million of charges associated with our environmental sites and $3.1 million of other miscellaneous charges.

Three Months Ended June 30, 2025:

Restructuring and other charges (income) includes restructuring charges of $13.0 million primarily related to Project Focus, which included $5.4 million of severance and employee separation costs, and accelerated depreciation of $2.5 million on assets identified for disposal in connection with the restructuring initiative, and $4.9 million of professional service provider costs and other miscellaneous charges. Other charges (income) of $23.7 million is comprised of $7.4 million of charges associated with our environmental sites, a charge of $11.9 million due to changes in our estimate for Furadan® disposal costs at our Middleport site, and $4.4 million of other miscellaneous charges.

Six Months Ended June 30, 2026:

Restructuring and other charges (income) includes restructuring charges of $234.0 million primarily comprised of $226.6 million in charges related to Project Foundation, which include non-cash asset write-off and accelerated depreciation costs of $198.9 million primarily associated with the planned exit of certain production activities, which includes a write-off of $70.6 million for certain receivables due to a change in our commercial strategy in Latin America; severance and employee separation costs of $11.5 million; and, other miscellaneous charges of $16.2 million, which includes contract exit costs and professional service provider costs partially offset by the cash proceeds from the sale of a legacy product line. During the six months ended June 30, 2026, we also recorded Project Focus-related costs of $7.2 million, primarily related to miscellaneous charges associated with previously implemented activities. Other charges (income) included $9.3 million of charges associated with our environmental sites and $0.6 million of other miscellaneous income.

Six Months Ended June 30, 2025

Restructuring and other charges (income) includes restructuring charges of $26.6 million primarily related to Project Focus, which included $9.6 million of severance and employee separation costs, accelerated depreciation of $5.6 million on assets identified for disposal in connection with the restructuring initiative, and $11.5 million of professional service provider costs and other miscellaneous charges. Other charges (income) of $27.9 million is comprised of $10.9 million of charges associated with our environmental sites, a charge of $11.9 million due to changes in our estimate for Furadan® disposal costs at our Middleport site, and $5.1 million of other miscellaneous charges.

(b)

Our non-operating pension, postretirement and other charges (income) includes those costs (benefits) related to interest, expected return on plan assets, amortized actuarial gains and losses and the impacts of any plan curtailments or settlements. These are excluded from our Adjusted earnings and are primarily related to changes in pension plan assets and liabilities which are tied to financial market performance and we consider these costs to be outside our operational performance. We continue to include the service cost and amortization of prior service cost in our Adjusted earnings results noted above. These elements reflect the current year operating costs to our businesses for the employment benefits provided to active employees.  

(c)

In July 2025, the Board of Directors approved a plan to divest the Company's commercial business in India in response to ongoing challenges in the country. In May 2026, the Company announced that it has signed a definitive agreement to sell the India commercial business to Crystal Crop Protection Limited for consideration of $252 million, subject to customary adjustments for cash, debt and working capital. The Company will continue to receive all cash generated from the ongoing operation of the India business until closing, primarily through monetization of working capital, and the sale is expected to close during 2026. The assets related to this business have been classified as held for sale since the third quarter of 2025. The business does not qualify for recognition as discontinued operations and will continue to be presented in the Company's reported GAAP results until a transaction is completed. Beginning with the third quarter of 2025, we have excluded the impact of various activities associated with the anticipated sale from our operating results for non-GAAP purposes. Refer to the table below for the adjustments related to the India held for sale business for the three and six months ended June 30, 2026.

Three Months Ended June 30,

Six Months Ended June 30,

Affected Line Item in the Consolidated
Statements of Income (Loss)

(In millions)

2026

2025

2026

2025

Operating results

$                 8.9

$                  —

$            43.0

$               —

Revenue, Cost of sales and services,
and Selling, general and
administrative expenses

Asset impairment

64.0

—

43.6

—

Restructuring and other charges
(income)

Third party provider costs

10.3

—

13.0

—

Restructuring and other charges
(income)

India held for sale business

$               83.2

$                  —

$            99.6

$               —

(d)

The income tax expense (benefit) on Corporate special charges (income) is determined using the applicable rates in the taxing jurisdictions in which the corporate special charge or income occurred and includes both current and deferred income tax expense (benefit) based on the nature of the non-GAAP performance measure.

(e)

Discontinued operations includes provisions, net of recoveries, for environmental liabilities and legal reserves and expenses related to previously discontinued operations and retained liabilities. 

(f)

We exclude the GAAP tax provision, including discrete items, from the non-GAAP measure of income, and include a non-GAAP tax provision based upon the projected annual non-GAAP effective tax rate. The GAAP tax provision includes certain discrete tax items including, but are not limited to: income tax expenses or benefits that are not related to continuing operating results in the current year; tax adjustments associated with fluctuations in foreign currency remeasurement of certain foreign operations; certain changes in estimates of tax matters related to prior fiscal years; certain changes in the realizability of deferred tax assets and related interim accounting impacts; and changes in tax law. In 2024 and 2023, we recorded significant deferred tax assets due to various tax incentives granted to the Company's Swiss subsidiaries (the "Swiss Tax Incentives"). The initial recognition of these Swiss Tax Incentives did not impact our adjusted non-GAAP effective tax rate but will be considered annually as we realize the benefits. Management believes excluding these discrete tax items, as well as the impacts of the Swiss Tax Incentives annually as the related benefits are realized, assists investors and securities analysts in understanding the tax provision and the effective tax rate related to continuing operating results thereby providing investors with useful supplemental information about FMC's operational performance.

Three Months Ended June 30,

Six Months Ended June 30,

(In millions)

2026

2025

2026

2025

Tax adjustments:

Revisions to valuation allowances of historical deferred tax assets (i)

$               —

$               —

$          124.7

$            (1.2)

Net impact of Switzerland tax incentives

6.4

10.5

0.9

13.3

Foreign currency remeasurement and other discrete items

15.7

(3.6)

32.8

9.1

Total non-GAAP tax adjustments

$            22.1

$              6.9

$          158.4

$            21.2

____________________

(i)

As a result of changes in global earnings mix and ongoing tax planning implemented in March 2026, we reevaluated the realizability of our historical deferred tax assets and recorded an increase to our valuation allowance in Switzerland of approximately $123 million during the six months ended June 30, 2026.

RECONCILIATION OF NET INCOME (LOSS) (GAAP) TO ADJUSTED EARNINGS FROM CONTINUING
OPERATIONS, BEFORE INTEREST, INCOME TAXES, DEPRECIATION AND
AMORTIZATION, AND NONCONTROLLING INTERESTS (NON-GAAP) (3)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

(In millions)

2026

2025

2026

2025

Net income (loss) (GAAP)

$         (186.3)

$             67.8

$      (467.5)

$          52.2

Restructuring and other charges (income) (1)

148.0

36.7

242.7

54.5

Non-operating pension, postretirement, and other charges
(income)

3.3

6.6

6.7

9.8

India held for sale business (2)

83.2

—

99.6

—

Discontinued operations, net of income taxes

(6.5)

(23.4)

13.4

(16.4)

Interest expense, net

71.3

61.0

136.1

111.1

Depreciation and amortization

41.1

43.4

83.1

87.1

Provision (benefit) for income taxes

(1.5)

14.4

110.6

27.9

Adjusted earnings from continuing operations, before interest,
income taxes, depreciation and amortization, and
noncontrolling interests (non-GAAP) (3)

$           152.6

$           206.5

$        224.7

$        326.2

___________________

(1)

In the reconciliation above, charges recorded in connection with the India held for sale business of $74.3 million and $56.6 million for the three and six months ended June 30, 2026, respectively, are presented in the India held for sale business line, as described in the reconciliation in note (c) above. On the consolidated statements of income (loss), these adjustments are recorded to "Restructuring and other charges (income)."

(2)

Beginning with the third quarter of 2025, we excluded the operating results of the India commercial business during the held for sale period for non-GAAP purposes. For further details on the charges and write-downs recorded in connection with the India held for sale business, refer to note (c) in the reconciliation above.

(3)

Referred to as Adjusted EBITDA. Defined as operating profit excluding restructuring and other charges (income), depreciation and amortization expense, and the India held for sale business.

RECONCILIATION OF CASH PROVIDED (REQUIRED) BY OPERATING ACTIVITIES OF
CONTINUING OPERATIONS (GAAP) TO FREE CASH FLOW (NON-GAAP) (2)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

(In millions)

2026

2025

2026

2025

Cash provided (required) by operating activities of continuing
operations (GAAP) (1)

$            363.0

$              65.9

$      (237.9)

$      (479.1)

Capital expenditures

(5.3)

(15.0)

(21.9)

(46.6)

Other investing activities

11.8

5.2

12.6

(0.6)

Capital additions and other investing activities

$                6.5

$               (9.8)

$          (9.3)

$        (47.2)

Cash provided (required) by operating activities of discontinued
operations

(18.6)

(16.4)

(34.3)

(29.7)

Divestiture transaction costs (2)

6.5

—

10.8

—

Free cash flow (non-GAAP) (3)

$            357.4

$              39.7

$      (270.7)

$      (556.0)

___________________

(1)

The three and six months ended June 30, 2026 includes cash payments of $26.1 million and $92.5 million, respectively, for restructuring activities primarily related to the Project Focus and Project Foundation transformation programs. The three and six months ended June 30, 2025 includes cash payments of $14.9 million and $70.6 million, respectively, made in connection with Project Focus.

(2)

Represents third party provider costs associated with the expected sale of our India commercial business. Proceeds from the sale of our India commercial business anticipated in 2026 will be excluded from free cash flow when received. Therefore, we have also excluded the related transaction costs from free cash flow.

(3)

Free cash flow is defined as cash provided (required) by operating activities of continuing operations (GAAP) adjusted for spending for capital additions and other investing activities as well as cash provided (required) by discontinued operations and divestiture transaction costs associated with the sale of our GSS business. We believe that this non-GAAP financial measure provides a useful basis for investors and securities analysts to evaluate the cash generated by routine business operations, including to assess our ability to repay debt, fund acquisitions and return capital to shareholders through share repurchases and dividends. Our use of free cash flow has limitations as an analytical tool and should not be considered in isolation or as a substitute for an analysis of our results under U.S. GAAP.

RECONCILIATION OF REVENUE (GAAP) 

TO REVENUE EXCLUDING INDIA (NON-GAAP) (2)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

(In millions)

2026

2025

2026

2025

Revenue (GAAP)

$               867.1

$            1,050.5

$            1,625.7

$            1,841.9

Less: Revenue from India commercial business (1)

25.7

—

21.9

—

Revenue excluding India (non-GAAP) (2)

$               841.4

$            1,050.5

$            1,603.8

$            1,841.9

___________________

(1)

Beginning with the third quarter of 2025, revenue from the India commercial business is excluded from our adjusted results during the held for sale period for non-GAAP purposes. Refer to note (c) above for further details. 

(2)

Although the India held for sale business does not qualify for recognition as discontinued operations, we believe Revenue excluding India (non-GAAP) provides management and investors with useful supplemental information regarding our ongoing revenue performance.

RECONCILIATION OF REVENUE CHANGE (GAAP) TO

ORGANIC REVENUE CHANGE (NON-GAAP) (1)

(Unaudited)

Three Months Ended June 30, 2026
vs. 2025

Six Months Ended June 30, 2026
vs. 2025

Total revenue (GAAP) change

(17) %

(12) %

Less: Revenue for India held for sale business for the three
and six months ended June 30, 2026

3 %

1 %

Revenue excluding India (non-GAAP) change (1)

(20) %

(13) %

Less:  Foreign currency impact

2 %

3 %

Organic revenue (non-GAAP) change (2)

(22) %

(16) %

___________________

(1)

Beginning with the third quarter of 2025, revenue from the India commercial business is excluded from our adjusted results during the held for sale period for non-GAAP purposes. Refer to note (c) above for further details. 

(2)

We believe organic revenue growth (non-GAAP) provides management and investors with useful supplemental information regarding our ongoing revenue performance and trends by presenting revenue growth excluding the impact of fluctuations in foreign exchange rates and the India held for sale business.

RECONCILIATION OF NET INCOME (LOSS) ATTRIBUTABLE TO

FMC STOCKHOLDERS (GAAP) TO RETURN ON INVESTED CAPITAL ("ROIC")

NUMERATOR (NON-GAAP) AND ADJUSTED ROIC (USING NON-GAAP NUMERATOR) (1)

(Unaudited)

Twelve Months Ended

(In millions, except percentages)

June 30, 2026

Net income (loss) attributable to FMC stockholders (GAAP)

$                     (2,758.0)

Interest expense, net, net of income taxes

225.4

Corporate special charges (income)

1,979.5

India held for sale business

621.3

Income tax expense (benefit) on Corporate special charges (income)

(195.6)

Discontinued operations attributable to FMC stockholders, net of income
taxes

66.4

Tax adjustments

553.5

ROIC numerator (non-GAAP)

$                          492.5

June 30, 2026

June 30, 2025

Total debt

$                       4,280.6

$                          4,163.3

Total FMC stockholders' equity

1,636.8

4,397.0

Total debt and FMC stockholders' equity (GAAP)

$                       5,917.4

$                          8,560.3

ROIC denominator (2 yr average total debt and FMC stockholders' equity)          

$                       7,238.9

ROIC (using Net income (loss) attributable to FMC stockholders (GAAP)
as numerator)

(38.10) %

Adjusted ROIC (using non-GAAP numerator) (1)

6.80 %

___________________

(1)

We believe Adjusted ROIC (non-GAAP) provides management and investors with useful supplemental information regarding our utilization of capital provided by both equity and debt as well as our working capital and free cash flow management. Additionally, vesting of certain restricted stock awards granted to officers is connected to Adjusted ROIC as a performance metric.

FMC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In millions)

June 30, 2026

December 31, 2025

Cash and cash equivalents

$                 476.6

$                 584.5

Trade receivables, net of allowance of $45.6 in 2026 and $43.3 in 2025     

2,070.5

2,062.0

Inventories

1,209.3

1,219.6

Prepaid and other current assets

570.7

481.2

Assets held for sale (1)

401.6

611.7

Total current assets

$              4,728.7

$              4,959.0

Property, plant and equipment, net

554.7

707.4

Other intangibles, net

2,307.9

2,361.8

Deferred income taxes

1,134.3

1,215.6

Other long-term assets

419.2

443.4

Total assets

$              9,144.8

$              9,687.2

Short-term debt and current portion of long-term debt

$                 326.3

$              1,305.1

Accounts payable, trade and other

657.8

771.0

Advanced payments from customers

35.5

453.1

Accrued and other liabilities

606.8

574.0

Accrued customer rebates

632.4

417.4

Guarantees of vendor financing

39.6

45.7

Accrued pensions and other postretirement benefits, current

3.3

3.3

Income taxes

43.1

24.0

Liabilities held for sale (1)

34.6

161.7

Total current liabilities

$              2,379.4

$              3,755.3

Long-term debt, less current portion

$              3,954.3

$              2,769.8

Long-term liabilities

1,150.0

1,063.2

Equity

1,661.1

2,098.9

Total liabilities and equity

$              9,144.8

$              9,687.2

___________________

(1)

The carrying value of the India held for sale business decreased from $450 million as of December 31, 2025 to $350 million as of June 30, 2026 primarily due to receivable collections during the period as well as an impairment charge of approximately $44 million. The carrying value of the held for sale business is comprised of $367 million of net assets held for sale as presented on the consolidated balance sheet and a gain of $17 million related to foreign currency translation in connection with the assets identified for disposal. The foreign currency translation gains are recorded in "Accumulated other comprehensive income (loss)" on the consolidated balance sheet and will be reclassified to the consolidated statement of income (loss) upon close of the sale.

FMC CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

Six Months Ended June 30,

(In millions)

2026

2025

Cash provided (required) by operating activities of continuing operations

$                (237.9)

$                (479.1)

Cash provided (required) by operating activities of discontinued operations

(34.3)

(29.7)

Cash provided (required) by investing activities of continuing operations

(10.0)

(51.4)

Cash provided (required) by financing activities of continuing operations

178.9

628.7

Effect of exchange rate changes on cash

(4.6)

12.4

Increase (decrease) in cash and cash equivalents

$                (107.9)

$                    80.9

Cash and cash equivalents, beginning of period

$                  584.5

$                  357.3

Cash and cash equivalents, end of period

$                  476.6

$                  438.2

SOURCE FMC Corporation

FMC (FMC - Free Report) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report, which is expected to be released on July 29, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis chemical producer is expected to post quarterly earnings of $0.21 per share in its upcoming report, which represents a year-over-year change of -69.6%.

Revenues are expected to be $909.57 million, down 13.4% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 4.69% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for FMC?For FMC, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -13.25%.

On the other hand, the stock currently carries a Zacks Rank of #5.

So, this combination makes it difficult to conclusively predict that FMC will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that FMC would post a loss of$0.39 per share when it actually produced a loss of -$0.23, delivering a surprise of +41.03%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

FMC doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

The submission marks an important milestone in FMC's efforts to advance next-generation weed control technologies as resistance pressure intensifies in key row crop markets.

, /PRNewswire/ -- FMC Corporation (NYSE: FMC), a leading global agricultural sciences company, today announced it has submitted the regulatory dossier for rimisoxafen to the United States (U.S.) Environmental Protection Agency (EPA), the first regulatory submission globally for this groundbreaking herbicide active ingredient. The U.S. submission covers use on corn, soybean, sunflower and select pulse crops.

"Filing the first regulatory dossier for rimisoxafen with the EPA represents a significant milestone for FMC," said Seva Rostovtsev, executive vice president and chief technology officer at FMC. "Years of innovation and scientific discovery have brought us to this point, and we are proud to advance this breakthrough dual mode of action technology through the regulatory process on behalf of growers facing increasingly complex weed resistance challenges."

Discovered at FMC's Stine Research Center and built on over a decade of biology research and more than 1,000 field and greenhouse studies, rimisoxafen is the first herbicide active ingredient ever classified as a dual mode of action by the Global Herbicide Resistance Action Committee (HRAC). Designated under Groups 12 and 32, rimisoxafen inhibits two distinct biochemical pathways in weeds, which helps delay resistance development compared to single mode of action herbicides.

Herbicide-resistant weeds continue to challenge growers and drive demand for new and underutilized modes of action. According to a 2025 Weed Science Society of America National Weed Survey, Palmer amaranth and waterhemp rank as the most troublesome broadleaf weeds in U.S. soybean production1. In extensive field testing, rimisoxafen has demonstrated consistent activity against both. The U.S. represents a critical market for next-generation weed control solutions with more than 70 million hectares of corn and soybeans grown annually and growers spending more than $6 billion annually on weed control.

Rimisoxafen is the third novel herbicide active ingredient FMC has advanced to regulatory submission in recent years, following Isoflex™ active and Dodhylex™ active. Together, these submissions reflect the depth and productivity of FMC's R&D pipeline and the company's commitment to advancing next-generation crop protection solutions through the regulatory process.

FMC intends to pursue regulatory submissions for rimisoxafen in additional key geographies and crop segments as part of its global development program. Timing and outcomes are subject to regulatory review and approval in each jurisdiction. Rimisoxafen is not currently registered for sale or use in the United States or any other country. No offer for sale, sale or use of this product is permitted prior to receipt of all required regulatory approvals.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

Dodhylex and Isoflex are trademarks of FMC Corporation and/or an affiliate. Always read and follow all label directions, restrictions and precautions for use. Products listed here may not be registered for sale or use in all states, countries or jurisdictions.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

1 Van Wychen, L. (2025). 2025 Survey of the Most Common and Troublesome Weeds in Broadleaf Crops, Fruits & Vegetables, and Hemp in the United States and Canada. Weed Science Society of America National Weed Survey Dataset. Available at: https://wssa.net/2025/11/wssa-survey-shows-an-urgent-need-for-new-weed-control-strategies/

SOURCE FMC Corporation

FMC Corporation Reaches Agreement for $400 Million Minority Equity Investment from Tessenderlo Group PR Newswire

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ --

FMC Corporation (NYSE: FMC) announced today it will release its second quarter 2026 earnings on Wednesday, July 29, 2026, after the stock market close via PR Newswire and the company's website https://investors.fmc.com.

The company will host a webcast conference call on Thursday, July 30, 2026, at 9:00 a.m. ET that is open to the public via internet broadcast and telephone.

Conference Call Details:

Internet broadcast: https://investors.fmc.com

United States (Local): +1 585 542 9983
United States (Toll-Free): +1 833 461 5787
Global Dial-In Numbers:  Global Dial-in Number
Access Code: 204774808

Pre-Registration Link:
https://events.q4inc.com/analyst/204774808?pwd=HsV6lDJU

Webcast Details:  
https://events.q4inc.com/attendee/204774808

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

SOURCE FMC Corporation

Also from this source

Key Takeaways FMC plans to sell its Newark property for about $114 million in gross proceeds.FMC will lease back its current facilities and use proceeds to reduce debt under its asset plan.FMC says its Stine Research Center and core R&D work will remain intact after the sale. FMC Corporation (FMC - Free Report) has announced a framework agreement to sell its property in Newark, DE, for roughly $114 million in gross proceeds. The transaction remains subject to a due diligence period, closing conditions, and adjustments.On completion, FMC plans to lease back the facilities it currently operates under a separate lease agreement while also retaining ownership of its adjacent properties in Maryland.

The decision arrived as a part of FMC’s ongoing effort to optimize its asset base by liquidating underutilized real estate and using the proceeds to reduce debt. The company will maintain its operations to continue on its growth strategy. FMC’s Stine Research Center, which serves as the global headquarters for its R&D organization, will continue operating at the Newark site after the transaction. The company stated that its scientific infrastructure, R&D capabilities and core research activities will remain fully intact.

The Stine Research Center will continue to play a central role in advancing FMC’s innovation pipeline. The company will now reduce its underutilized space while improving the world-class facilities and infrastructure.

The transaction reflects FMC’s commitment to strengthening its balance sheet while preserving investments that support long-term growth. The deal is expected to close in the fourth quarter of 2026. However, FMC noted that the leaseback and operational terms are still in the preliminary stage of negotiations, and there is no guarantee that the transaction will ultimately be completed.

FMC shares have slumped 73.8% over the past year against the industry’s 3.9% growth.

Image Source: Zacks Investment Research

FMC’s Zacks Rank & Key PicksFMC currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Basic Materials space are Albemarle Corporation (ALB - Free Report) , Dow Inc. (DOW - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) .

While ALB and DOW sport a Zacks Rank #1 (Strong Buy) each at present, ASM carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for ALB’s 2026 earnings is pinned at $12.39 per share, indicating a 1,668.35% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 74.5%. ALB’s shares have jumped 148.4% over the past year.

The Zacks Consensus Estimate for DOW’s 2026 earnings is pegged at $2.61 per share, indicating a rise of 377.66% year over year. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters. DOW’sshares have gained 13.1% over the past year.

The Zacks Consensus Estimate for ASM’s current fiscal-year earnings is pinned at 39 cents per share, indicating a 34.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 125%.

Key Takeaways FMC and Corteva signed a co-exclusive deal to expand rimisoxafen access in the Americas.Corteva will prepay $200 million as FMC retains ownership and supplies the active ingredient.Rimisoxafen-based products are expected to see first commercial sales by decade's end. FMC Corporation (FMC - Free Report) and Corteva, Inc. have announced a co-exclusive strategic supply and license agreement to expand access to FMC’s rimisoxafen herbicide technology across North and South America. The collaboration is expected to help herbicide-resistant weed management solutions for corn and soybean markets while adding to the portfolios of these two leading global agricultural science and innovation companies.

Under the agreement, FMC will retain ownership of rimisoxafen and supply the active ingredient to Corteva. Both companies will independently develop and commercialize exclusive premix formulations for corn and soybean markets throughout the region. Corteva will make an initial prepayment of $200 million for future product supply.

Rimisoxafen has been recognized by the Herbicide Resistance Action Committee as the industry’s first dual mode of action herbicide. Its unique design provides a higher barrier to resistance development compared to traditional single-mode of action products.

The partnership will play a critical role in broadening access to this groundbreaking innovation to control threats to crop yields and farm profitability. Pending regulatory approvals, the first commercial sales of rimisoxafen-based products are anticipated by the end of the decade. The partnership reflects both companies’ commitment to providing sustainable and effective weed management solutions for farmers across the Americas.

FMC shares have plunged 71.3% over the past year against the industry’s 2.9% growth.

Image Source: Zacks Investment Research

FMC’s Zacks Rank & Key PicksFMC currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the Basic Materials space are Albemarle Corporation (ALB - Free Report) , Dow Inc. (DOW - Free Report) and Avino Silver & Gold Mines Ltd. (ASM - Free Report) .

While ALB and DOW sport a Zacks Rank #1 (Strong Buy) each at present, ASM carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

The Zacks Consensus Estimate for ALB’s 2026 earnings is pinned at $12.39 per share, indicating a 1,668.35% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 74.5%. ALB’s shares have jumped 180.4% over the past year.

The Zacks Consensus Estimate for DOW’s 2026 earnings is pegged at $2.61 per share, indicating a rise of 377.66% year over year. Its earnings beat the Zacks Consensus Estimate in three of the trailing four quarters. DOW’sshares have gained 14.1% over the past year.

The Zacks Consensus Estimate for ASM’s current fiscal-year earnings is pinned at 39 cents per share, indicating a 34.48% year-over-year increase. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with an average surprise of 125%.

Shares of agricultural chemical producer FMC Corporation (FMC +6.65%) rallied 16.8% in March, according to data from S&P Global Market Intelligence.

FMC entered March having lost significant value, with the stock having declined 72% in 2025. Last year, a crop down-cycle combined with a significant number of FMC products coming off-patent, leading to pricing pressure and lower margins.

However, the war in Iran, which broke out Feb. 28, has led to a supply crunch for certain agricultural chemical inputs, which appears to be benefiting FMC. In addition, the company's CEO appeared at an industry conference, where he said that a good-sized number of buyers were considering FMC as a potential acquisition target.

Today's Change

(

6.65

%) $

0.75

Current Price

$

12.02

FMC gets a commodities-related bounce, plus buyout talk In mid-March at the JPMorgan & Chase Industrials conference, FMC CEO Pierre Brondeau said that banks -- likely, investment banks that help broker acquisitions -- were in discussions with between five and 10 parties about a potential acquisition of FMC.

That being said, Brondeau also noted that FMC's shareholders were divided over a potential sale. After all, FMC is down significantly from its highs and has new chemicals in its development pipeline. Investors may wish to see those research and development efforts come to fruition before considering a buyout.

Still, the fact that so many parties were interested in the company might have surprised public market investors, who may have bid the stock up, given that buyout interest may lower the risk of further price declines.

And of course, the war in Iran, which broke out on the last day of February, certainly helped some commodity companies, FMC included. That's because shortly after the war began, Iran's leadership declared that any ship passing through the Strait of Hormuz would be attacked.

The Strait of Hormuz is the small waterway between Iran and Oman through which 20% of the world's oil flows. But in addition to oil, the strait is also a crucial waterway for the transport of other commodities, such as urea and ammonia, which are used to make fertilizers. That has tightened the market for agricultural chemicals a bit, which would help U.S.-based FMC. That being said, the impact on the fertilizer industry has been much more modest than on the energy industry.

Image source: Getty Images.

Can FMC continue coming back? Even though the overall picture looks better for FMC now, it's still a risky bet. The company has $4.1 billion in debt, a substantial amount on top of its $2.2 billion market cap. Furthermore, we won't really know how much FMC will benefit from the current supply crunch until the company reports earnings. Wall Street analysts only expect the benefit to be minimal, so the company could disappoint when it reports.

That being said, there is some cause for optimism. On April 6, FMC announced that its new herbicide, Isoflex, had been approved in the European Union. While Isoflex had already been approved in other geographies, the EU approval could set the company up for better financial results for the rest of this year.

All in all, FMC remains an interesting turnaround candidate, but with high risk, given the various uncertainties surrounding the war, competition, and cyclicality of the agriculture industry, as well as the desire of buyers to make a bid for the company.

On April 17, 2026, Old North State Wealth Management disclosed selling its entire FMC Corporation (FMC +6.65%) stake, an estimated $4.42 million trade based on quarterly average pricing.

What happenedAccording to a recent SEC filing, Old North State Wealth Management eliminated its entire stake in FMC Corporation (FMC +6.65%) by selling 295,829 shares in the first quarter. The estimated transaction value was approximately $4.42 million, based on the quarterly average share price from January through March 2026. The quarter-end value of the position dropped by $4.10 million, reflecting the combined effect of the sale and underlying price movement.

What else to knowTop holdings after the filing:NYSE: LYB: $9.62 million (4.5% of AUM)NASDAQ: AAPL: $8.10 million (3.7% of AUM)NASDAQ: AMZN: $7.02 million (3.2% of AUM)NASDAQ: NVDA: $6.88 million (3.2% of AUM)NYSE: BA: $6.76 million (3.1% of AUM)As of April 16, 2026, FMC shares were priced at $17.58, down 50% over the past year and significantly underperforming the S&P 500’s roughly 35% gain in the same period.Company overviewMetricValueRevenue (TTM)$3.47 billionNet Income (TTM)($2.24 billion)Price (as of market close April 16, 2026)$17.58Company snapshotFMC Corporation offers crop protection chemicals, including insecticides, herbicides, fungicides, biologicals, crop nutrition, and seed treatment products.The company generates revenue primarily through the development, marketing, and sale of agricultural inputs aimed at enhancing crop yield and quality, with distribution via a direct sales force and strategic partners.Main customers include growers, distributors, and professional pest and turf management providers across North America, Latin America, EMEA, and Asia.FMC Corporation is an agricultural sciences company serving a diverse client base with a suite of crop protection and plant health solutions. FMC Corporation offers a broad product portfolio of crop protection, plant health, and professional pest and turf management products.

What this transaction means for investorsThis sale appears more like a strategic exit to cut losses than just regular portfolio rebalancing, which is important for long-term investors to consider. When a fund completely divests from a position after experiencing a significant 50% drop, it often indicates diminishing confidence in a potential recovery, rather than mere portfolio adjustments.

The company's current situation sheds light on this. FMC is undergoing a challenging reset, with annual revenue dropping 18% to around $3.47 billion, resulting in a net loss of $2.24 billion, mainly due to impairments and restructuring efforts. Even moving forward, management expects another revenue decline, projecting 2026 figures to be between $3.6 billion and $3.8 billion, alongside an adjusted EBITDA decrease of up to 17%. They are also considering strategic alternatives, including a possible sale, while aiming to trim $1 billion in debt through asset disposals. Putting this in perspective regarding the portfolio, FMC was never a core holding, with an investment of about $4.4 million, especially when compared to larger stakes like LyondellBasell at $9.6 million. This type of sentiment can make the exit easier to execute.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amazon, Apple, Boeing, and Nvidia and is short shares of Apple. The Motley Fool has a disclosure policy.

, /PRNewswire/ -- FMC Corporation (NYSE: FMC) announced today that its board of directors declared a regular quarterly dividend of 8 cents per share, payable on July 16, 2026, to shareholders of record as of the close of business on June 30, 2026.   

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made.  Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaims any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

SOURCE FMC Corporation

FMC (FMC - Free Report) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +40.72%. A quarter ago, it was expected that this chemical producer would post earnings of $1.21 per share when it actually produced earnings of $1.2, delivering a surprise of -0.83%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

FMC, which belongs to the Zacks Agriculture - Operations industry, posted revenues of $758.6 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 5.10%. This compares to year-ago revenues of $791.4 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

FMC shares have added about 10% since the beginning of the year versus the S&P 500's gain of 4.3%.

What's Next for FMC?While FMC has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for FMC was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.40 on $968.24 million in revenues for the coming quarter and $1.70 on $3.67 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Agriculture - Operations is currently in the top 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Archer Daniels Midland (ADM - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on May 5.

This agribusiness giant is expected to post quarterly earnings of $0.66 per share in its upcoming report, which represents a year-over-year change of -5.7%. The consensus EPS estimate for the quarter has been revised 2% higher over the last 30 days to the current level.

Archer Daniels Midland's revenues are expected to be $21.11 billion, up 4.6% from the year-ago quarter.

FMC Corporation (FMC) Q1 2026 Earnings Call Transcript

, /PRNewswire/ -- FMC Corporation (NYSE:FMC), a leading global agricultural sciences company, announced today it has signed a definitive agreement to sell FMC India Private Limited (FMC India) to Crystal Crop Protection Limited, a crop solutions company in India, for consideration of $252 million USD, subject to customary adjustments for cash, debt and working capital. FMC will continue to receive all cash generated from the ongoing operation of the India business until closing, primarily through monetization of working capital.

In July 2025, FMC announced its decision to divest the company's crop protection commercial business in India, enabling FMC to participate in the Indian market through a new go-to-market approach while deploying resources to its highest-growth opportunities globally. The transaction is expected to close by year-end 2026, subject to regulatory approval and other customary closing conditions. FMC intends to allocate all proceeds from the sale to debt reduction.

"Crystal Crop Protection Limited is well-positioned to serve Indian farmers with FMC's portfolio of innovative technologies, and we look forward to supporting their growth through our supply agreement," said Pierre Brondeau, FMC chairman, chief executive officer and president. "FMC remains committed to India and will continue to conduct global R&D activities and maintain global manufacturing operations in the country."

Through this transaction, Crystal Crop Protection Limited will acquire FMC India's commercial operations in the crop protection field, including a license to FMC's brands sold in India. Crystal Crop Protection Limited will also receive a preferred supply agreement for certain FMC active ingredients and formulated products, as well as preferred access to FMC's pipeline of active ingredients in India for the crop protection field.

"We are excited on signing this definitive agreement to acquire this business of FMC in India," said Ankur Aggarwal, chairman and managing director, Crystal Crop Protection Limited. "We look forward to welcoming a talented workforce into the Crystal group and aim at accelerating innovation across both chemical and biological domains of crop protection. FMC's innovative portfolio, blockbuster brands and future pipeline give us an opportunity to provide Indian farmers access to innovative products. We look forward to further enhancing and building on our relationship with FMC."

BofA Securities acted as exclusive financial adviser while Davis Polk & Wardwell LLP served as U.S. legal adviser and Khaitan & Co assisted as legal adviser for FMC on this transaction. EY acted as exclusive buy side M&A adviser to Crystal Crop Protection Limited and Shardul Amarchand Mangaldas & Co served as legal adviser. Further terms and conditions of the agreement were not disclosed.

About FMC

FMC Corporation is a global agricultural sciences company dedicated to helping growers produce food, feed, fiber and fuel for an expanding world population while adapting to a changing environment. FMC's innovative crop protection solutions – including biologicals, crop nutrition, digital and precision agriculture – enable growers and crop advisers to address their toughest challenges economically while protecting the environment. FMC is committed to discovering new herbicide, insecticide and fungicide active ingredients, product formulations and pioneering technologies that are consistently better for the planet. Visit fmc.com to learn more and follow us on LinkedIn®.

About Crystal Crop Protection Limited
Established in 1994, Crystal Crop Protection Limited is a crop solutions company with agrochemicals and seeds at the core of its offerings. It operates on a fully integrated model, that integrates robust synthesis research and development in crop protection products and natural crop solutions as well as robust seeds breeding program, with backward-integrated technology enabled manufacturing and pan-India distribution, with a farmer-centric approach. To learn more, visit www.crystalcropprotection.com

Statement under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995: FMC and its representatives may from time to time make written or oral statements that are "forward-looking" and provide other than historical information, including statements contained in this press release, in FMC's other filings with the SEC, and in presentations, reports or letters to FMC stockholders.

In some cases, FMC has identified these forward-looking statements by such words or phrases as "outlook", "will likely result," "is confident that," "expect," "expects," "should," "could," "may," "will continue to," "believe," "believes," "anticipates," "predicts," "forecasts," "estimates," "projects," "potential," "intends" or similar expressions identifying "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including the negative of those words or phrases. Such forward-looking statements are based on our current views and assumptions regarding future events, future business conditions and the outlook for the company based on currently available information. The forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. These statements are qualified by reference to the risk factors included in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Form 10-K"), the section captioned "Forward-Looking Information" in Part II of the 2025 Form 10-K and to similar risk factors and cautionary statements in all other reports and forms filed with the Securities and Exchange Commission ("SEC"). We wish to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. Forward-looking statements are qualified in their entirety by the above cautionary statement.

We specifically decline to undertake any obligation, and specifically disclaim any duty, to publicly update or revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events, except as may be required by law.

SOURCE FMC Corporation

FMC Corporation (FMC) Presents at 21st Annual Global Farm to Market Conference Transcript

Agricultural chemicals specialist FMC (FMC +6.65%) wasn't an investor darling over the past few trading days. Mr. Market was displeased with the company's announcement that it was floating a new issue of debt securities, a flotation that was soon upsized; largely as a result, its shares were trading 9% lower week to date as of Friday afternoon, according to data compiled by S&P Global Market Intelligence.

Increasing the debt burden On Tuesday, FMC announced the impending flotation of $750 million aggregate principal amount of senior secured notes.

Image source: Getty Images.

The issue, intended for private investors, will mature in 2031. Two days later, the company significantly increased the principal to $1.2 billion and revealed that the interest rate was 8%. The issue is expected to close on Friday, June 5.

FMC said that the proceeds of the sale will fund repurchases and redemptions of an existing senior notes issue, which, in contrast to the new notes flotation, is unsecured. That matures this Oct. 1 and pays out at a rate of 3.2%. FMC added that the monies raised will additionally be used to retire other borrowings. It also aims to use these funds for "general corporate purposes."

Today's Change

(

6.65

%) $

0.75

Current Price

$

12.02

Not great for the balance sheet Taking on debt that'll cost 8% to retire, while borrowing pays out at just over 3%, is not going to do wonders for either FMC's balance sheet or its profit and loss statement (the latter is where a company records interest payments).

And while it's admirable that the company can finagle a higher principal amount, it's going to add that much more weight to its existing debt burden. I'd be leery, to say the least, about investing in FMC stock these days.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Agricultural chemical producer FMC Corp. (FMC +6.65%) has had a difficult run in the markets. Over the past couple of years, FMC has seen some of its proprietary chemicals come off-patent. At the same time, the agriculture industry has experienced a difficult crop cycle, with low prices making it difficult for farmers to invest in additional chemicals.

Add in a fair amount of debt, and FMC's stock has plummeted 90% from its early 2022 highs.

However, FMC just announced an asset sale this month that could alleviate some of the debt pressure. With tightening global markets and a bargain-basement stock price, could the sale signal the beginning of a turnaround?

Today's Change

(

6.65

%) $

0.75

Current Price

$

12.02

On May 7, FMC announced that it would sell its Indian business to Crystal Crop Protection Limited, a crop chemical company based in India, for $252 million. The deal is supposed to close by the end of this year. As part of the deal, Crystal will take over FMC's commercial operations in India, while retaining a license to FMC's brands and preferred access to FMC's research and development pipeline.

FMC first announced its intention to sell its Indian business in July 2025 to reduce debt and avoid the issues that had plagued it. Last year, the company took back excess inventory that had built up in the Indian sales channel, resulting in a massive revenue reversal and decline in earnings. FMC slashed its dividend by 92% as a result.

The sale of the business will help the company avoid that complicated market, and also make a small dent in its debt load. As of March 31, FMC had over $4.5 billion in debt, so the India sale will cut that total by just about 5.6%. While only a small reduction in debt, every little bit helps.

Image source: Getty Images.

FMC's turnaround is tenuous FMC could use any help the market offers. Last quarter, both revenue and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) fell year over year, and the first quarter of last year was not that great to begin with.

There is some optimism that FMC will benefit from the closure of the Strait of Hormuz, as that should tighten the global fertilizer market. However, those benefits didn't show up in the first quarter.

FMC is also open to selling its business outright, with its CEO stating in March that there were multiple interested parties in the company's research pipeline.

All in all, the sale of the India business is a positive step in FMC's attempted turnaround. However, it's a small one. FMC's survival will depend on how it navigates this difficult environment, the success of its new molecules in development, and whether the company attracts a buyout at a fair price. All of those are still big question marks.

FMC Corporation (FMC) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript